Zymeworks shifts to royalty-driven model, authorizes $125M buyback; appoints Platshon as CIO

Zymeworks Inc.

Eligible for up to $440M in near-term milestones from Ziihera GEA approvals ($250M US, $100M EU, $75M Japan, $15M China).
Board authorized $125M share repurchase program; prior $60M buyback retired ~4.4M shares (6% of outstanding).
Cash and investments $299.4M as of Sep 30, 2025; with milestones expects to fund operations beyond 2028.
Scott Platshon stepped down from board, appointed Acting CIO to manage healthcare asset aggregation strategy.
Also eligible for up to $434M in additional milestones from J&J for pasritamig Phase 3 program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.